Key factors for effective mitotane therapy in children with adrenocortical carcinoma

in Endocrine-Related Cancer
View More View Less
  • 1 Paediatric and Adolescent Medicine, Faculty of Medicine, University Medical Centre Augsburg, Augsburg, Germany
  • | 2 Department of Paediatric Haematology and Oncology, University Children’s Hospital, Otto-von-Guericke-University, Magdeburg, Germany
  • | 3 Clinic of Paediatrics, Klinikum Dortmund, University Witten/Herdecke, Dortmund, Germany
  • | 4 Paediatric Haematology/Oncology, Department of Paediatrics, University Hospital Tuebingen, Tuebingen, Germany

Contributor Notes

Correspondence should be addressed to M Kuhlen or A Redlich: michaela.kuhlen@uk-augsburg.de or Antje.Redlich@med.ovgu.de
Restricted access

USD  $0.00
USD  $0.00

USD  $0.00
USD  $0.00

USD  $0.00
USD  $0.00

USD  $0.00
USD  $0.00

USD  $0.00
USD  $0.00

USD  $0.00
USD  $0.00

USD  $0.00
USD  $0.00

USD  $0.00
USD  $0.00

Adjuvant treatment with mitotane and chemotherapy is recommended for paediatric advanced and metastatic adrenocortical carcinoma (ACC). Yet, questions on the indication, dosage, and length of therapy are unanswered. Data from the German Paediatric Oncology Haematology-Malignant Endocrine Tumour studies were analysed retrospectively for patients receiving mitotane during first- and/or second-line therapy. Forty-three patients were identified (median age: 7.5 years (range: 0.2–17.8); 29 female) with median follow-up of 2.2 years (range: 0.04–12.71). Three-year overall (OS) and progression-free survival (PFS) were 44.9% and 28.5%, respectively. Eleven of 43 patients received mitotane as neoadjuvant treatment, and 4/11 tumours reached partial remission (PR). Twenty-seven of 43 patients received mitotane combined with chemotherapy in an adjuvant setting resulting in PR of measurable target lesions in 5/13 patients. Metastatic disease (hazard ratio (HR): 3.2; 95% CI: 1.2–18.6; P = 0.018), duration of mitotane treatment <9 months (HR: 5.6; 95% CI: 1.9–16.9; P = 0.002), and not achieving drug target range (TR) (HR: 28.5; 95% CI: 5.4–150.3; P < 0.001) significantly impacted as negative prognostic factors upon PFS and OS (metastatic disease: HR: 4.9; 95% CI: 1.6–15.5; P = 0.006; duration of mitotane treatment: HR: 7.0: 95% CI 1.9–26.0; P = 0.004; TR not reached: HR: 13.5; 95% CI 3.6–50.3; P < 0.001). Cox regression determined the risk of event decreasing by 10.4% for each month of mitotane treatment (P = 0.015). Re-treatment with mitotane after first-line treatment proved ineffective. The duration of mitotane treatment and reaching mitotane TR significantly impacted survival. Improving the efficacy of mitotane, including appropriate indications, needs to be evaluated in prospective randomized trials.

 

Society for Endocrinology logo

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 1262 1262 595
Full Text Views 38 38 14
PDF Downloads 45 45 12
  • Cecchetto G, Ganarin A, Bien E, Vorwerk P, Bisogno G, Godzinski J, Dall’Igna P, Reguerre Y, Schneider D & Brugieres L et al.2017 Outcome and prognostic factors in high-risk childhood adrenocortical carcinomas: a report from the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT ). Pediatric Blood and Cancer 64 e26368. (https://doi.org/10.1002/pbc.26368)

    • Search Google Scholar
    • Export Citation
  • Dall’Igna P, Virgone C, De Salvo GL, Bertorelle R, Indolfi P, De Paoli A, Buffa P, Conte M, Esposito G & Inserra A et al.2014 Adrenocortical tumors in Italian children: analysis of clinical characteristics and P53 status. Data from the National Registries. Journal of Pediatric Surgery 49 13671371. (https://doi.org/10.1016/j.jpedsurg.2014.03.006)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Dickstein G, Shechner C, Arad E, Best LA & Nativ O 1998 Is there a role for low doses of mitotane (o,p’-DDD) as adjuvant therapy in adrenocortical carcinoma? Journal of Clinical Endocrinology and Metabolism 83 31003103. (https://doi.org/10.1210/jcem.83.9.5113)

    • Search Google Scholar
    • Export Citation
  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S & Mooney M et al.2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 45 228247. (https://doi.org/10.1016/j.ejca.2008.10.026)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Faria AM & Almeida MQ 2012 Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults. Molecular and Cellular Endocrinology 351 5257. (https://doi.org/10.1016/j.mce.2011.09.040)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, Haak HR, Mihai R, Assie G & Terzolo M 2018 European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the study of adrenal tumors. European Journal of Endocrinology 179 G1G46. (https://doi.org/10.1530/EJE-18-0608)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Ferreira AM, Brondani VB, Helena VP, Charchar HLS, Zerbini MCN, Leite LAS, Hoff AO, Latronico AC, Mendonca BB & Diz MDPE et al.2019 Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation. Journal of Steroid Biochemistry and Molecular Biology 190 250255. (https://doi.org/10.1016/j.jsbmb.2019.04.011)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Fragoso MC, Almeida MQ, Mazzuco TL, Mariani BM, Brito LP, Goncalves TC, Alencar GA, Lima Lde Lde O, Faria AM & Bourdeau I et al.2012 Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. European Journal of Endocrinology 166 6167. (https://doi.org/10.1530/EJE-11-0806)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ & Krans HM 1994 Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. British Journal of Cancer 69 947951. (https://doi.org/10.1038/bjc.1994.183)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y & Blondeau P 1990 Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New England Journal of Medicine 322 11951201. (https://doi.org/10.1056/NEJM199004263221705)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Martins-Filho SN, Almeida MQ, Soares I, Wakamatsu A, Alves VAF, Fragoso MCBV & Zerbini MCN 2021 Clinical impact of pathological features including the Ki-67 labeling index on diagnosis and prognosis of adult and pediatric adrenocortical tumors. Endocrine Pathology 32 288300. (https://doi.org/10.1007/s12022-020-09654-x)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • McAteer JP, Huaco JA & Gow KW 2013 Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) Program study. Journal of Pediatric Surgery 48 10251031. (https://doi.org/10.1016/j.jpedsurg.2013.02.017)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Michalkiewicz E, Sandrini R, Figueiredo B, Miranda EC, Caran E, Oliveira-Filho AG, Marques R, Pianovski MA, Lacerda L & Cristofani LM et al.2004 Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. Journal of Clinical Oncology 22 838845. (https://doi.org/10.1200/JCO.2004.08.085)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Miele E, Di Giannatale A, Crocoli A, Cozza R, Serra A, Castellano A, Cacchione A, Cefalo MG, Alaggio R & De Pasquale MD 2020 Clinical, genetic, and prognostic features of adrenocortical tumors in children: a 10-year single-center experience. Frontiers in Oncology 10 554388. (https://doi.org/10.3389/fonc.2020.554388)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Picard C, Faure-Conter C, Leblond P, Brugieres L, Thomas-Teinturier C, Hameury F, Defachelles AS, Verschuur A, Brisse HJ & Sarnacki S et al.2020 Exploring heterogeneity of adrenal cortical tumors in children: the French Pediatric Rare Tumor Group (Fracture) experience. Pediatric Blood and Cancer 67 e28086. (https://doi.org/10.1002/pbc.28086)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Pinto EM, Chen X, Easton J, Finkelstein D, Liu Z, Pounds S, Rodriguez-Galindo C, Lund TC, Mardis ER & Wilson RK et al.2015 Genomic landscape of paediatric adrenocortical tumours. Nature Communications 6 6302. (https://doi.org/10.1038/ncomms7302)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Pinto EM, Figueiredo BC, Chen W, Galvao HCR, Formiga MN, Fragoso MCBV, Ashton-Prolla P, Ribeiro EMSF, Felix G & Costa TEB et al.2020 XAF1 as a modifier of p53 function and cancer susceptibility. Science Advances 6 eaba3231. (https://doi.org/10.1126/sciadv.aba3231)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Puglisi S, Calabrese A, Basile V, Ceccato F, Scaroni C, Altieri B, Della Casa S, Loli P, Pivonello R & De Martino MC et al.2020 Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma. Cancers 12 740. (https://doi.org/10.3390/cancers12030740)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Redlich A, Boxberger N, Strugala D, Fruhwald MC, Leuschner I, Kropf S, Bucsky P & Vorwerk P 2012 Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial. Klinische Padiatrie 224 366371. (https://doi.org/10.1055/s-0032-1327579)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Ribeiro RC, Pinto EM, Zambetti GP & Rodriguez-Galindo C 2012 The International Pediatric Adrenocortical Tumor Registry initiative: contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Molecular and Cellular Endocrinology 351 3743. (https://doi.org/10.1016/j.mce.2011.10.015)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Rodriguez-Galindo C, Krailo MD, Pinto EM, Pashankar F, Weldon CB, Huang L, Caran EM, Hicks J, McCarville MB & Malkin D et al.2021 Treatment of pediatric adrenocortical carcinoma with surgery, retroperitoneal lymph node dissection, and chemotherapy: the Children’s Oncology Group ARAR0332 protocol. Journal of Clinical Oncology 39 24632473. (https://doi.org/10.1200/JCO.20.02871)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Sandrini R, Ribeiro RC & DeLacerda L 1997 Childhood adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 82 20272031. (https://doi.org/10.1210/jcem.82.7.4057)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Teinturier C, Pauchard MS, Brugieres L, Landais P, Chaussain JL & Bougneres PF 1999 Clinical and prognostic aspects of adrenocortical neoplasms in childhood. Medical and Pediatric Oncology 32 106111. (https://doi.org/10.1002/(sici)1096-911x(199902)32:2<106::aid-mpo7>3.0.co;2-j)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P & Grossrubatscher E et al.2007 Adjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine 356 23722380. (https://doi.org/10.1056/NEJMoa063360)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Virgone C, Roganovic J, Vorwerk P, Redlich A, Schneider DT, Janic D, Bien E, López-Almaraz R, Godzinski J & Osterlundh G et al.2021 Adrenocortical tumours in children and adolescents: the EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatric Blood and Cancer 68 (Supplement 4) e29025. (https://doi.org/10.1002/pbc.29025)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Wieneke JA, Thompson LD & Heffess CS 2003 Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. American Journal of Surgical Pathology 27 867881. (https://doi.org/10.1097/00000478-200307000-00001)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Zambaiti E, Duci M, De Corti F, Gamba P, Dall’Igna P, Ghidini F & Virgone C 2021 Clinical prognostic factors in pediatric adrenocortical tumors: a meta-analysis. Pediatric Blood and Cancer 68 e28836. (https://doi.org/10.1002/pbc.28836)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Zancanella P, Pianovski MA, Oliveira BH, Ferman S, Piovezan GC, Lichtvan LL, Voss SZ, Stinghen ST, Callefe LG & Parise GA et al.2006 Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. Journal of Pediatric Hematology/Oncology 28 513524. (https://doi.org/10.1097/01.mph.0000212965.52759.1c)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation